|
|
Volumn , Issue 7 MAR, 2013, Pages
|
|
Helping oxytocin deliver: Considerations in the development of oxytocin-based therapeutics for brain disorders
|
|
Author keywords
Drug development; Humans; Intranasal administration; Oxytocin; Pharmacology; Psychiatry
|
|
Indexed keywords
3,4 METHYLENEDIOXYMETHAMPHETAMINE;
ANTIDEPRESSANT AGENT;
ARGIPRESSIN;
ATYPICAL ANTIPSYCHOTIC AGENT;
BUSPIRONE;
CARBETOCIN;
CHOLECYSTOKININ;
CLOZAPINE;
CYCLOSERINE;
DIZOCILPINE;
HYDROCORTISONE;
KETAMINE;
LIPOSOME;
NELIVAPTAN;
NEUROLEPTIC AGENT;
NEUROPEPTIDE;
OXYTOCIN;
OXYTOCIN RECEPTOR;
PLACEBO;
PROPRANOLOL;
SEROTONIN UPTAKE INHIBITOR;
UNCLASSIFIED DRUG;
VASOPRESSIN RECEPTOR;
VASOPRESSIN RECEPTOR ANTAGONIST;
VASOPRESSIN V1A RECEPTOR;
VASOPRESSIN V1B RECEPTOR;
VASOPRESSIN V2 RECEPTOR;
WAY 277464;
ADDICTION;
ANXIETY DISORDER;
ARTICLE;
AUTISM;
BLOOD BRAIN BARRIER;
BLOOD SAMPLING;
BRAIN DISEASE;
CENTRAL NERVOUS SYSTEM;
CEREBROSPINAL FLUID;
DEVELOPMENTAL DISORDER;
DRUG ABSORPTION;
DRUG DELIVERY SYSTEM;
DRUG DESIGN;
DRUG DISTRIBUTION;
DRUG DOSE TITRATION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG METABOLISM;
DRUG POTENCY;
DRUG SAFETY;
ENZYME IMMUNOASSAY;
FUNCTIONAL MAGNETIC RESONANCE IMAGING;
GENERALIZED ANXIETY DISORDER;
HEART RATE VARIABILITY;
HUMAN;
HYDROCORTISONE BLOOD LEVEL;
MENTAL DISEASE;
MENTAL PATIENT;
MOOD DISORDER;
NONHUMAN;
PERSONALITY DISORDER;
PHARMACODYNAMICS;
POSITIVE AND NEGATIVE SYNDROME SCALE;
POSITRON EMISSION TOMOGRAPHY;
POSTTRAUMATIC STRESS DISORDER;
PREPULSE INHIBITION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SCHIZOPHRENIA;
SINGLE DRUG DOSE;
SOCIAL PHOBIA;
TRANQUILIZING ACTIVITY;
TRANSLATIONAL RESEARCH;
TREATMENT DURATION;
|
|
EID: 84878782313
PISSN: 16624548
EISSN: 1662453X
Source Type: Journal
DOI: 10.3389/fnins.2013.00035 Document Type: Article |
|
Times cited : (146)
|
|
References (0)
|
